Bridging the Iron Deficiency Chasm in Heart Failure: The Revolutionary Role of Intravenous Iron in Optimizing Outcomes

Aurora, CO US
September 11, 2021

Target Audience

Physicians, Nurses, Nurse Practitioners, Pharmacists, Scientists, and Health Care Professionals who specialize or have an interest in heart failure.

Learning Objectives

 

1) Discuss the basic principles of iron metabolism and absorption, and understand the complex pathophysiology of iron deficiency (ID) in heart failure (HF), with a focus on inflammation, hepcidin, and the subsequent impact on the clinical utility of oral vs. IV iron supplementation modalities in HF.

2) Recognize the robust impact of comorbid ID and HF, and describe the practical prognostic manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.

3) Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID, and differentiate the practical distinctions between functional and absolute iron deficiency.

4) Appraise existing, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal trials that have influenced current practice and consensus guidelines for ID management in HF (ESC and ACC/AHA/HFSA).

5) Distinguish among the FDA-approved IV iron agents, including recent dosing recommendations, indications, and the pharmacologic nuances that yield unique clinical utility and impact.

6) Using a real-world, case-based format, analyze the evolving placement of IV iron products in the HF treatment calculus, with emphasis on the evidence-driven translation of recent trial data into clinical practice.

Additional Information

AttachmentSize
PDF icon AR21HFSA Combined Deck Handout.pdf1.97 MB
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
Course opens: 
08/01/2021
Course expires: 
09/30/2021
Event starts: 
09/11/2021 - 8:15am
Event ends: 
09/11/2021 - 9:30am
Rating: 
0

5 mins   Welcome and Introductions/Pre-test
                Stefan D. Anker, MD, PhD (Activity Chair)

15 mins   Embracing Pivotal Pillars of Change: The Clinical Gravity and Key Pathophysiologic Underpinnings of ID in Heart Failure  
                Muthiah Vaduganathan, MD, MPH

25 mins   Navigating Novel Heart Failure Horizons with Effective Iron Repletion: Where We’ve Been & Where We’re Going
                 Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP

20 mins   Case-based Clinical Perspectives on ID & HF: The Paradigm-Shifting Impact of Intravenous Iron on HF Management  
                Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP

10 mins   Conversations with the Experts/Audience Q&A/Post-test
                Stefan D. Anker, MD, PhD (Activity Chair)

 

Gaylord Rockies Resort
6700 N Gaylord Blvd
Aurora, CO 80019
United States

Stefan D. Anker, MD, PhD (Activity Chair) 
Professor of Cardiology and Cachexia Research,
Department of Cardiology
Charite University
Berlin, Germany

 

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Medicine Chief, DeBakey VA Medical Center
Houston, TX

Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP 
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine 
Bronx, NY


Muthiah Vaduganathan, MD, MPH
Instructor in Medicine
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, MA

 

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity

 

 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
Please login or register to take this course.